Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Variability in functional p53 reactivation by PRIMA-1(Met)/APR-246 in Ewing sarcoma.

British journal of cancer - 12 Nov 2013

Aryee D N T, Niedan S, Ban J, Schwentner R, Muehlbacher K, Kauer M, Kofler R, Kovar H

Abstract excerpt

BACKGROUND: Though p53 mutations are rare in ES, there is a strong indication that p53 mutant tumours form a particularly bad prognostic group. As such, novel treatment strategies are warranted that would specifically target and eradicate tumour cells containing mutant p53 in this subset of ES patients. METHODS: PRIMA-1(Met), also known as APR-246, is a small organic molecule that has been shown to restore...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Agents
Share to Bone Neoplasms
Share to Gene Knockdown Techniques

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Microarray Analysis

Share to RNA, Small Interfering

Share to Sarcoma, Ewing

Share to Transcriptome

Share to Tumor Cells, Cultured

Source

Open in PubMed Open full text

Identifiers

PMID: 24129240
DOI: 10.1038/bjc.2013.635
PMCID: PMC3833220

Genes

APOL6
PCDH7
PENK

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Variability in functional p53 reactivation by PRIMA-1(Met)/APR-246 in Ewing sarcoma.PMID 24129240Read ↗

PRIMA-1 and PRIMA-1Met (APR-246): From Mutant/Wild Type p53 Reactivation to Unexpected Mechanisms Underlying Their Potent Anti-Tumor Effect in Combinatorial TherapiesSemantic proximity Read ↗

The Mutant p53-Targeting Compound APR-246 Induces ROS-Modulating Genes in Breast Cancer CellsSemantic proximity Read ↗

RETRA exerts anticancer activity in Ewing's sarcoma cells independent of their TP53 status.Semantic proximity Read ↗

The anti-cancer agent APR-246 can activate several programmed cell death processes to kill malignant cells.Semantic proximity Read ↗

The anti-cancer agent APR-246 can activate several programmed cell death processes to kill malignant cellsSemantic proximity Read ↗

Mutant p53 reactivation by PRIMA-1MET induces multiple signaling pathways converging on apoptosis.Semantic proximity Read ↗

p53 reactivating small molecule PRIMA‑1MET/APR‑246 regulates genomic instability in MDA‑MB‑231 cells.Semantic proximity Read ↗

Antitumor Effects of PRIMA-1 and PRIMA-1Met (APR246) in Hematological Malignancies: Still a Mutant P53-Dependent Affair?Semantic proximity Read ↗

APR-246 potently inhibits tumour growth and overcomes chemoresistance in preclinical models of oesophageal adenocarcinoma.Semantic proximity Read ↗

PRIMA-1met (APR-246) inhibits growth of colorectal cancer cells with different p53 status through distinct mechanismsSemantic proximity Read ↗

APR-246/PRIMA-1(MET) rescues epidermal differentiation in skin keratinocytes derived from EEC syndrome patients with p63 mutations.Semantic proximity Read ↗

Synergistic effects of PRIMA-1Met (APR-246) and 5-azacitidine in TP53-mutated myelodysplastic syndromes and acute myeloid leukemiaSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.